Sun Pharma Share Price Target 2026, 2027, 2030, 2040, 2050

One of India’s leading pharmaceutical businesses, Sun Pharmaceutical Industries Ltd., makes specialized generic drugs worldwide. Many investors are intrigued by Sun Pharma future share price goals.

This article will examine Sun Pharma fundamentals, expert projections, and share price estimates for 2024, 2025, 2030, 2040, and 2050.

What is Sun Pharmaceutical Industries Ltd NSE: SUNPHARMA?

Sun Pharmaceutical Industries Ltd., located in Mumbai, India, trades as SUNPHARMA on the India National Stock Exchange. Sun Pharma, founded in 1983, is India’s biggest pharmaceutical firm in market valuation and revenue. Generic, over-the-counter, anti-retroviral, and API medications are its specialties.

Fundamental Table

Metric	Value
Market Cap	₹446,520 crore
P/E Ratio	42.49
EPS	₹43.45
Dividend Yield	0.73%
ROCE	15.04%
ROE	15.04%
Debt to Equity	0.04

Key Metrics Table

Metric	Value
52 Week High	₹1,873.35
52 Week Low	₹1,068.35
Book Value per Share	₹265.49
Price to Book Value	7.03
Free Float	45.52%
Promoter Holding	54.48%

Peers & Comparison Table

Company	Market Cap (₹ Cr)	P/E Ratio	ROE (%)
Sun Pharma	446,520	42.49	15.04
Dr Reddy	109,319	19.64	19.74
Cipla	132,332	30.75	15.43
Lupin	48,660	42.41	7.35
Aurobindo Pharma	45,328	20.44	9.73

Sun Pharma share price

Sun Pharma share price Target 2026

Sun Pharma could profit from its robust product pipeline and growing penetration in developing countries in 2025. The company’s biosimilar and specialised product expenditures should pay off, raising share prices. In 2026, its share price target would be ₹2395, as per stock market analysts.

According to stock market analysts, its share price would be between ₹1553 to ₹2395 in 2026.

Year	Minimum Price (Rs)	Maximum Price (Rs)
2026	1553	2395

Month	Minimum Price  (Rs)	Maximum Price (Rs)
January	1614	1886
February	1553	1984
March	1632	2025
April	1754	2074
May	1825	2121
June	1931	2155
July	1988	2174
August	2012	2232
September	2101	2274
October	2157	2332
November	2190	2360
December	2210	2395

Sun Pharma share price Target 2030

Sun Pharma to be a worldwide pharmaceutical leader by 2030. Long-term R&D, smart acquisitions, and high-value market emphasis could boost growth. We predict Sun Pharma share price to reach between ₹3,500 and ₹4,500 by 2030.

Year	Minimum Price (₹)	Maximum Price (₹)
2030	3,500	4,500

Month	Minimum Price (₹)	Maximum Price (₹)
January	3,500	3,600
February	3,550	3,650
March	3,600	3,700
April	3,650	3,750
May	3,700	3,800
June	3,750	3,850
July	3,800	3,900
August	3,850	3,950
September	3,900	4,000
October	3,950	4,100
November	4,000	4,300
December	4,200	4,500

Share Price Target 2050

Projecting 2050 share values requires conjecture owing to the lengthy time horizon. We can predict a range if Sun Pharma continues its growth track and reacts to market changes. Sun Pharma might become a worldwide pharmaceutical giant by 2050, with a share price between ₹10,000 and ₹15,000.

Year	Minimum Price (₹)	Maximum Price (₹)
2050	10,000	15,000

Month	Minimum Price (₹)	Maximum Price (₹)
January	10,000	10,500
February	10,200	10,700
March	10,400	10,900
April	10,600	11,100
May	10,800	11,300
June	11,000	11,500
July	11,200	11,700
August	11,400	11,900
September	11,600	12,100
October	11,800	12,500
November	12,000	13,000
December	12,500	15,000

Should I buy Sun Pharma stock?

Year	Minimum Price (₹)	Maximum Price (₹)
2026	1553	2395
2030	3,500	4,500
2050	10,000	15,000

Many considerations must be considered while buying Sun Pharma shares. The company market position, product pipeline, and worldwide presence might boost growth. Investors should also consider regulatory issues, price concerns, and pharmaceutical industry competitiveness. Before investing, investigate and analyze your financial objectives.

Sun Pharmaceutical Industries Ltd earning results

Sun Pharma has consistently performed financially. Recent quarterly performance summary:

Quarter	Revenue (₹ Cr)	Net Profit (₹ Cr)	EPS (₹)
Q2 FY24	12,192	2,375	9.91
Q1 FY24	11,519	2,061	8.60
Q4 FY23	10,844	1,984	8.28
Q3 FY23	11,241	2,166	9.04

Expert forecasts on the future of Sun Pharmaceutical Industries Ltd.

Industry analysts are optimistic about Sun Pharma future. Many analysts expect the company specialist product emphasis, R&D spending, and developing market development to generate long-term growth. Important expert projections include:

1. Continued specialized expansion, especially dermatology and ophthalmology.
2. Market share growth in the US, India, and developing markets.
3. Cost reductions and product mix improvements may boost margins.
4. Patent cliffs for some branded medications provide biosimilar and complicated generic opportunities.
5. Possible strategic acquisitions to boost product and market share.

Is Sun Pharma stock good to buy? (bull case & bear case)

Bull Case:

1. Strong Indian market position and expanding worldwide exposure
2. Strong specialized and complicated generic pipeline
3. Continuous R&D investment for innovation and growth
4. Strong financial sheet, minimal debt
5. Operational efficiency and product mix may boost margins.

Bear Case:

1. Regulatory concerns in important markets, including US FDA inspection
2. Increased generic drug competition causes price pressures
3. International revenue changes due to currency volatility
4. Depending on a few core goods for most revenue
5. Possible integration issues from future purchases

Conclusion

Sun Pharmaceutical Industries Ltd. is a worldwide pharmaceutical leader. With its strong market position, concentration on specialist goods, and smart R&D expenditures, the firm is poised for development. This article’s share price projections are based on current trends and expert analysis, but investors should remember that the stock market is unpredictable and vulnerable to internal and external influences. Before investing, you must study, assess your risk tolerance, and contact a financial expert.

FAQs